Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Castrate Resistant Prostate Cancer × Lenograstim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Breast Neoplasms 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Seminoma 1 Prostate Cancer Metastatic 1 Ovarian Neoplasms 1 Neutropenia 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Endodermal Sinus Tumor 1 Central Nervous System Neoplasms 1 Castrate Resistant Prostate Cancer 1

Interventions

Melphalan 1 Lenograstim 1 1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01907009 2023-04-19

MEL-CAP

Barts & The London NHS Trust

Phase 2/3 Terminated

Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡